Surveillance Bronchoscopy in Lung Transplantation Recipients: A Single Center Experience Analysis
Bronchoscopy with bronchoalveolar lavage and transbronchial biopsy is the gold standard for the diagnosis of infection or acute cellular rejection in lung transplantation (LTx) recipients, but there is some controversy to perform it in asymptomatic patients. We conducted a retrospective analysis of...
Saved in:
| Published in: | Transplantation proceedings Vol. 52; no. 5; pp. 1380 - 1383 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01-06-2020
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Bronchoscopy with bronchoalveolar lavage and transbronchial biopsy is the gold standard for the diagnosis of infection or acute cellular rejection in lung transplantation (LTx) recipients, but there is some controversy to perform it in asymptomatic patients. We conducted a retrospective analysis of medical reports of LTx recipients who survived in the first year after transplant during the period of August 2003 to February 2018 to evaluate the applicability of this procedure in the management of asymptomatic acute cellular rejection in our center. We assessed 1252 bronchoscopies of 247 patients during this period, and, facing the histopathological results, we defined our management that included conservative or intervention therapy. In our service the information obtained by surveillance bronchoscopy was sufficient to modify the management mainly in the first 2 surveillance bronchoscopies (second and sixth week post LTx). This effect seems to dilute after the second month, making its applicability more questionable.
•Bronchoscopy with transbronchial biopsy is the gold standard for the diagnosis of acute cellular rejection in lung transplant recipients; however, there is some controversy about performing it in asymptomatic patients.•The major complication for long-term survival of lung transplant recipients is chronic allograft dysfunction, and acute cellular rejection represents one of the most important risk factors for this complication.•In our experience, the information obtained with surveillance bronchoscopy is important to modify the management mainly in the second and sixth week post lung transplant. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 0041-1345 1873-2623 |
| DOI: | 10.1016/j.transproceed.2020.02.029 |